Intriguingly, a Swedish company has been planning a Phase 2 trial for a drug termed a fractalkine receptor inhibitor to prevent hyperinflammation in COVID-19 patients, and thereby Acute Respiratory Distress Syndrome (46). Here, CX3CR1 is linked to acute respiratory distress syndrome.